2019
Vedolizumab Achieved Clinical and Histologic Remission in a Patient with Lung Cancer Who Had a Steroid-Refractory Upper Gastrointestinal Injury Due to Nivolumab Treatment
Tran C, Abu-Sbeih H, Luo W, Lu Y, Wang Y. Vedolizumab Achieved Clinical and Histologic Remission in a Patient with Lung Cancer Who Had a Steroid-Refractory Upper Gastrointestinal Injury Due to Nivolumab Treatment. Journal Of Immunotherapy And Precision Oncology 2019, 2: 40-45. DOI: 10.4103/jipo.jipo_18_18.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsLung cancerSteroid courseAdverse eventsAbstract Immune checkpoint inhibitorsUpper GI adverse eventsSignificant anti-tumor effectGI adverse eventsProgressive lung cancerUpper gastrointestinal injuryUpper GI toxicityAnti-tumor effectsNovel therapeutic classResolution of inflammationGI-irAEsHistologic remissionHistological remissionNivolumab treatmentVedolizumab treatmentCheckpoint inhibitorsClinical remissionGastrointestinal injuryGI toxicityPrednisone taperSevere nausea
2018
Outcomes of Vedolizumab Treatment in Patients With Immune Checkpoint Inhibitor-Induced Diarrhea and Colitis: A Multi-Center Study
Abu-Sbeih H, Ali F, Alsaadi D, Jennings J, Luo W, Gong Z, Richards D, Charabaty A, Wang Y. Outcomes of Vedolizumab Treatment in Patients With Immune Checkpoint Inhibitor-Induced Diarrhea and Colitis: A Multi-Center Study. The American Journal Of Gastroenterology 2018, 113: s58. DOI: 10.14309/00000434-201810001-00110.Peer-Reviewed Original Research